CONTACT US
Home > Inhibitors/Agonists> > Emorfazone
38957-41-4-Emorfazone Emorfazone

Emorfazone

For research use only. Not for therapeutic Use.

  • CAT Number: I026830
  • CAS Number: 38957-41-4
  • Molecular Formula: C11H17N3O3
  • Molecular Weight: 239.275
  • Purity: 98%
Inquiry Now
Related Small Molecules: Glyburide (Glibenclamide)     Glutarimide-Isoindolinone-NH-PEG4-COOH     Linvencorvir    

Emorfazone (Cat.No:I026830) is a synthetic opioid analgesic that exhibits both analgesic and sedative properties. It is commonly used for the relief of moderate to severe pain. Emorfazone acts by binding to opioid receptors in the central nervous system, thereby reducing pain perception and producing a calming effect. 


Catalog Number I026830
CAS Number 38957-41-4
Synonyms

Emorfazone; M 73101; M73101

Molecular Formula C11H17N3O3
Purity 98%
Solubility Soluble in DMSO
Appearance Solid powder
Storage Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
IUPAC Name 3(2H)-Pyridazinone, 4-ethoxy-2-methyl-5-morpholino-
InChI InChI=1S/C11H17N3O3/c1-3-17-10-9(8-12-13(2)11(10)15)14-4-6-16-7-5-14/h8H,3-7H2,1-2H3
InChIKey URJQOOISAKEBKW-UHFFFAOYSA-N
SMILES O=C1C(OCC)=C(N2CCOCC2)C=NN1C
Reference

1: Piaz VD, Vergelli C, Giovannoni MP, Scheideler MA, Petrone G, Zaratin P. 4-Amino-3(2H)-pyridazinones bearing arylpiperazinylalkyl groups and related compounds: synthesis and antinociceptive activity. Farmaco. 2003 Nov;58(11):1063-71. PubMed PMID: 14572856.
2: Takaya M, Sato M. [Studies on pyridazinone derivatives. XVI. Analgesic-antiinflammatory activities of 3(2H)-pyridazinone derivatives]. Yakugaku Zasshi. 1994 Feb;114(2):94-110. Japanese. PubMed PMID: 8169774.
3: Khan AA, Malik S, Zuberi NI. Double blind study on emorfazone and ibuprofen in dental pain and inflammation. J Pak Med Assoc. 1992 Jan;42(1):17-8. PubMed PMID: 1545477.
4: Hiranuma T, Kato S, Hachisu M. Analgesic action of amfenac Na, a non-steroidal anti-inflammatory agent. J Pharmacobiodyn. 1988 Sep;11(9):612-9. PubMed PMID: 3265150.
5: Maki Y, Shimada K, Sako M, Kitade Y, Hirota K. Photochemical oxidation of 4-ethoxy-2-methyl-5-morpholino-3(2H)-pyridazinone (Emorfazone) by pyrimido[5,4-g]pteridine 5-oxide. An attempt to apply a functional chemical model for biological oxidations to drug-metabolism studies. Chem Pharm Bull (Tokyo). 1988 May;36(5):1714-20. PubMed PMID: 3203412.
6: Yonehara N, Shibutani T, Inoki R. Contribution of substance P to heat-induced edema in rat paw. J Pharmacol Exp Ther. 1987 Sep;242(3):1071-6. PubMed PMID: 2443642.
7: Hatano M, Yamada T, Yoshida A, Miyata K, Okusawa S, Hoya I, Miura K, Ishihara M. [Studies on isolated rat hepatocytes (6)]. Josai Shika Daigaku Kiyo. 1984;13(1):156-64. Japanese. PubMed PMID: 6596968.
8: Hayashi T, Amino M, Ikoma Y. Changes of metabolism and substrate-binding spectrum of emorfazone between immature and mature guinea-pigs. Xenobiotica. 1983 Aug;13(8):461-6. PubMed PMID: 6649679.
9: Hayashi T. Metabolism of 4-ethoxy-2-methyl-5-morpholino-3(2H)-pyridazinone (emorfazone). V. Effect of inducer pretreatment on oxygenation of the morpholino moiety in guinea pigs. Chem Pharm Bull (Tokyo). 1982 Oct;30(10):3748-56. PubMed PMID: 7160018.
10: Sato M. Effects of emorfazone on the nociceptive response induced by bradykinin in rats and dogs. Arch Int Pharmacodyn Ther. 1982 Jun;257(2):200-12. PubMed PMID: 6956248.
11: Sato M, Yamaguchi A. Studies on mechanisms of action of emorfazone. Effects on the release of bradykinin-like substance in thermic edema of rat paws. Arzneimittelforschung. 1982;32(4):379-82. PubMed PMID: 7201806.
12: Sato M, Kataoka M, Yamaguchi A. Pituitary-adrenocortical stimulation and anti-inflammatory actions of 4-ethoxy-2-methyl-5-morpholino-3(2H)-pyridazinone (M73101). J Pharmacobiodyn. 1981 Sep;4(9):649-55. PubMed PMID: 6278121.
13: Sato M, Ishizuka Y, Yamaguchi A. Pharmacological investigations of 4-ethoxy-2-methyl-5-morpholino-3(2H)-pyridazinone (M 73101), a new analgesic and anti-inflammatory drug. Arzneimittelforschung. 1981;31(10):1738-45. PubMed PMID: 6172134.
14: Hayashi T, Amino M, Yamaguchi A, Ohki M. [Metabolism of 4-ethoxy-2-methyl-5-morpholino-3(2H)-pyridazinone (M73101), a new anti-inflammatory agent. IV. Plasma concentration and absorption in various animals (author’s transl)]. Yakugaku Zasshi. 1980 Jan;100(1):105-9. Japanese. PubMed PMID: 7373521.
15: Sato M. [Pharmacological studies of 4-ethoxy-2-methyl-5-morpholino-3(2H)-pyridazinone (M73101). (5) Action of M73101 on the central nervous system (author’s transl)]. Nihon Yakurigaku Zasshi. 1979 Oct;75(7):695-706. Japanese. PubMed PMID: 575516.
16: Ishizuka Y, Sato M, Tanizawa H. [Pharmacological studies of 4-ethoxy-2-methyl-5-morpholino-3(2H)-pyridazinone (M73101). (4). Enzyme induction (author’s transl)]. Nihon Yakurigaku Zasshi. 1979 Sep;75(6):633-43. Japanese. PubMed PMID: 120300.
17: Onodera C, Hayashi T, Makita I, Hashi T, Takeda K, Ozeki F, Shimazu H. [Chronic toxicity test of 4-ethoxy-2-methyl-5-morpholino-3(2H)-pyridazinone (M73101) in beagle dogs (author’s transl)]. J Toxicol Sci. 1979 Aug;4(3):229-53. Japanese. PubMed PMID: 317111.
18: Sato M, Ishizuka Y, Tanizawa H, Fukuda T, Yuizono T. [Pharmacological studies of 4-ethoxy-2-methyl-5-morpholino-3(2H)-pyridazinone (M73101). (3). General pharmacological actions (author’s transl)]. Nihon Yakurigaku Zasshi. 1979 Apr 20;75(3):291-307. Japanese. PubMed PMID: 317064.
19: Sato M, Ishizuka Y, Seki K, Tanizawa H, Fukuda T, Yuizono T. [Pharmacological studies of 4-ethoxy-2-methyl-5-morpholino-3(2H)-pyridazinone (M73101). (2). Anti-inflammatory activity (author’s transl)]. Nihon Yakurigaku Zasshi. 1979 Mar;75(2):127-46. Japanese. PubMed PMID: 395049.

Request a Quote